139 related articles for article (PubMed ID: 38279411)
1. Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study.
Nash P; Coates LC; Fleishaker D; Kivitz AJ; Mease PJ; Gladman DD; FitzGerald O; Wang C; Wu J; Hsu MA; Menon S; Fallon L; Kanik KS
Lancet Rheumatol; 2021 Apr; 3(4):e270-e283. PubMed ID: 38279411
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study.
Nash P; Coates LC; Kivitz AJ; Mease PJ; Gladman DD; Covarrubias-Cobos JA; FitzGerald O; Fleishaker D; Wang C; Wu J; Hsu MA; Menon S; Fallon L; Romero AB; Kanik KS
Rheumatol Ther; 2020 Sep; 7(3):553-580. PubMed ID: 32506317
[TBL] [Abstract][Full Text] [Related]
3. Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance.
Nash P; Mease PJ; Fleishaker D; Wu J; Coates LC; Behrens F; Gladman DD; Kivitz AJ; Wei JC; Shirinsky I; Menon S; Romero AB; Fallon L; Hsu MA; Wang C; Kanik KS
Lancet Rheumatol; 2021 Jan; 3(1):e28-e39. PubMed ID: 38273637
[TBL] [Abstract][Full Text] [Related]
4. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
Yamanaka H; Tanaka Y; Takeuchi T; Sugiyama N; Yuasa H; Toyoizumi S; Morishima Y; Hirose T; Zwillich S
Arthritis Res Ther; 2016 Jan; 18():34. PubMed ID: 26818974
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.
Wollenhaupt J; Lee EB; Curtis JR; Silverfield J; Terry K; Soma K; Mojcik C; DeMasi R; Strengholt S; Kwok K; Lazariciu I; Wang L; Cohen S
Arthritis Res Ther; 2019 Apr; 21(1):89. PubMed ID: 30953540
[TBL] [Abstract][Full Text] [Related]
6. Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies.
Gladman DD; Charles-Schoeman C; McInnes IB; Veale DJ; Thiers B; Nurmohamed M; Graham D; Wang C; Jones T; Wolk R; DeMasi R
Arthritis Care Res (Hoboken); 2019 Oct; 71(10):1387-1395. PubMed ID: 31112005
[TBL] [Abstract][Full Text] [Related]
7. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.
Helliwell P; Coates LC; FitzGerald O; Nash P; Soriano ER; Elaine Husni M; Hsu MA; Kanik KS; Hendrikx T; Wu J; Kudlacz E
Arthritis Res Ther; 2018 Oct; 20(1):242. PubMed ID: 30373651
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials.
Kivitz AJ; FitzGerald O; Nash P; Pang S; Azevedo VF; Wang C; Takiya L
Clin Rheumatol; 2022 Feb; 41(2):499-511. PubMed ID: 34510295
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study.
Leng X; Lin W; Liu S; Kanik K; Wang C; Wan W; Jiang Z; Liu Y; Liu S; Zhang Z; Zhang Z; Xu J; Tan W; Hu J; Li J; Liu J; Gunay LM; Dina O; Kinch C; Zeng X
RMD Open; 2023 Jan; 9(1):. PubMed ID: 36720560
[TBL] [Abstract][Full Text] [Related]
10. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
Ramanan AV; Quartier P; Okamoto N; Foeldvari I; Spindler A; Fingerhutová Š; Antón J; Wang Z; Meszaros G; Araújo J; Liao R; Keller S; Brunner HI; Ruperto N; ;
Lancet; 2023 Aug; 402(10401):555-570. PubMed ID: 37423231
[TBL] [Abstract][Full Text] [Related]
11. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
Mease P; Hall S; FitzGerald O; van der Heijde D; Merola JF; Avila-Zapata F; Cieślak D; Graham D; Wang C; Menon S; Hendrikx T; Kanik KS
N Engl J Med; 2017 Oct; 377(16):1537-1550. PubMed ID: 29045212
[TBL] [Abstract][Full Text] [Related]
12. An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data.
Burmester GR; Curtis JR; Yun H; FitzGerald O; Winthrop KL; Azevedo VF; Rigby WFC; Kanik KS; Wang C; Biswas P; Jones T; Palmetto N; Hendrikx T; Menon S; Rojo R
Drug Saf; 2020 Apr; 43(4):379-392. PubMed ID: 32006348
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Fleischmann R; Mysler E; Hall S; Kivitz AJ; Moots RJ; Luo Z; DeMasi R; Soma K; Zhang R; Takiya L; Tatulych S; Mojcik C; Krishnaswami S; Menon S; Smolen JS;
Lancet; 2017 Jul; 390(10093):457-468. PubMed ID: 28629665
[TBL] [Abstract][Full Text] [Related]
14. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
Gladman D; Rigby W; Azevedo VF; Behrens F; Blanco R; Kaszuba A; Kudlacz E; Wang C; Menon S; Hendrikx T; Kanik KS
N Engl J Med; 2017 Oct; 377(16):1525-1536. PubMed ID: 29045207
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trial.
Cohen SB; Pope J; Haraoui B; Irazoque-Palazuelos F; Korkosz M; Diehl A; Rivas JL; Lukic T; Liu S; Stockert L; Iikuni N; Keystone EC
Lancet Rheumatol; 2019 Sep; 1(1):e23-e34. PubMed ID: 38229356
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies.
Nash P; Coates LC; Fleischmann R; Papp KA; Gomez-Reino JJ; Kanik KS; Wang C; Wu J; Menon S; Hendrikx T; Ports WC
Rheumatol Ther; 2018 Dec; 5(2):567-582. PubMed ID: 30414064
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib: A Review in Psoriatic Arthritis.
Paik J; Deeks ED
Drugs; 2019 Apr; 79(6):655-663. PubMed ID: 30895473
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment.
Sandborn WJ; Lawendy N; Danese S; Su C; Loftus EV; Hart A; Dotan I; Damião AOMC; Judd DT; Guo X; Modesto I; Wang W; Panés J
Aliment Pharmacol Ther; 2022 Feb; 55(4):464-478. PubMed ID: 34854095
[TBL] [Abstract][Full Text] [Related]
19. Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme.
Sandborn WJ; D'Haens GR; Sands BE; Panaccione R; Ng SC; Lawendy N; Kulisek N; Modesto I; Guo X; Mundayat R; Su C; Vranic I; Panés J
J Crohns Colitis; 2023 Apr; 17(3):338-351. PubMed ID: 36124702
[TBL] [Abstract][Full Text] [Related]
20. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
Burmester GR; Blanco R; Charles-Schoeman C; Wollenhaupt J; Zerbini C; Benda B; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Soma K; Bradley J; Mebus C;
Lancet; 2013 Feb; 381(9865):451-60. PubMed ID: 23294500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
